Citius Pharmaceuticals Inc (CTXR)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Citius Pharmaceuticals Inc chart...

About the Company

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

Employees

10

CEO

Myron Holubiak

Exchange

NASDAQ

Website

www.citiuspharma.com

$M

Total Revenue

10

Employees

$138M

Market Capitalization

-5.31

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CTXR News

Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts

22h ago, source:

Citius Pharmaceuticals, Inc. (CTXR) announced the FDA has accepted the resubmission of the Biologics License Application for LYMPHIR, ...

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

1mon ago, source: KOIN 6

NOTE: This content is not written by or endorsed by "KOIN", its advertisers, or Nexstar Media Inc.

Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials

1mon ago, source: Yahoo Finance

Citius Pharmaceuticals Inc (NASDAQ:CTXR) reported a decrease in R&D expenses, reflecting the completion of certain clinical trials, but saw an increase in G&A expenses due to pre-launch activities.

Citius Pharmaceuticals Inc (CTXR)

12d ago, source: Investing

Investing.com - Citius Pharma (NASDAQ: CTXR) reported third quarter EPS of $-0.060, in line with the analyst estimate of $-0.060. Revenue for the quarter came in at $0.00 versus... Citius Pharma ...

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

2mon ago, source: Morningstar

About Citius Pharmaceuticals, Inc. Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company ...

Citius Pharmaceuticals Inc CTXR

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

2mon ago, source: Stockhouse

Likewise, our upcoming end of Phase 2 meeting with the FDA should provide valuable input on the development plan for Halo-Lido," stated Leonard Mazur, Chairman and CEO of Citius. "Importantly, we ...

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

1mon ago, source: ADVFN

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...